| Basics |
Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.
|
| IPO Date: |
March 3, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$944.8M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.40 | 2.83%
|
| Avg Daily Range (30 D): |
$0.44 | 3.93%
|
| Avg Daily Range (90 D): |
$0.41 | 3.30%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.53M |
| Avg Daily Volume (30 D): |
2.14M |
| Avg Daily Volume (90 D): |
1.83M |
| Trade Size |
| Avg Trade Size (Sh.): |
87 |
| Avg Trade Size (Sh.) (30 D): |
93 |
| Avg Trade Size (Sh.) (90 D): |
88 |
| Institutional Trades |
| Total Inst.Trades: |
2,892 |
| Avg Inst. Trade: |
$2.32M |
| Avg Inst. Trade (30 D): |
$2.12M |
| Avg Inst. Trade (90 D): |
$2.73M |
| Avg Inst. Trade Volume: |
.13M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.83M |
| Avg Closing Trade (30 D): |
$3.92M |
| Avg Closing Trade (90 D): |
$4.07M |
| Avg Closing Volume: |
154.93K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.98
|
$-.98
|
|
Diluted EPS
|
|
$-.98
|
$-.98
|
|
Revenue
|
$
|
$ 20.04M
|
$ 12.5M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -84.85M
|
$ -84.13M
|
|
Operating Income / Loss
|
$
|
$ -83.76M
|
$ -89.58M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -.09M
|
$ 27.62M
|
|
PE Ratio
|
|
|
|
|
|
|
